Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation t…
Biotechnology
US, Cambridge [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Cogent Biosciences, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2018 | - | -5.896 | - | 8 | - | -469 | - | 1 | - | 1 | - | 9 |
| 2019 | -5.5500 | -5.410 | 9 | 10 | -34 | -430 | -34 | 2 | -36 | 2 | 7 | 12 |
| 2020 | -3.9700 | -3.842 | 22 | 7 | -30 | -306 | -30 | 1 | -32 | 1 | 10 | 9 |
| 2023 | -2.2600 | -2.320 | 0 | 0 | -132 | -192 | -134 | 0 | -153 | 0 | 26 | 0 |
| 2024 | -2.4200 | -2.430 | 0 | 0 | -192 | -192 | -205 | 0 | -211 | 0 | 34 | 0 |
| 2025 | - | -2.310 | - | 1 | - | -181 | - | 0.30 | - | 0.30 | - | 1 |
| 2026 | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F61/td> | - | 2.F61 | - | 2.F61 |
| 2027 | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F71/td> | - | 1.F71 | - | 1.F71 |
| 2028 | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F81/td> | - | 0.F81 | - | 0.F81 |